Pfizer Inc. has declared that its experimental antiviral pill for COVID-19 cut rates off hospitalisation and death by nearly 90% in high-risk adults, as the pharmaceutical company joined the race for an easy-to-use treatment against the coronavirus.
BREAKING: Pfizer says its experimental COVID-19 pill cut hospitalization and death by 90% and will seek authorization from the U.S. Food and Drug Administration and international regulators.https://t.co/wDVaLwk9lF
— The Associated Press (@AP) November 5, 2021
To this day, most COVID-19 treatments are done by intravenous or injections. These pills are clearly an innovation in the fight against the spread of the coronavirus. The UK recently approved a pill Merck has developed, and it is currently under review by the Food Drugs and Administration.
Pfizer has had excellent results, so good that Independent experts are recommending the company to stop the study, since the results are solid. Once Pfizer applies, this product could get approved within weeks to months by the FDA and other international regulators.
Since the beginning of the COVID-19 pandemic, researchers have been racing to create a pill that will treat the coronavirus at home, to ease the symptoms, speed up the recovery and help keep people out of the hospital. These pills seem to be able to do just that.
Pfizer shares went up 8% once they announced the success of their study.